Compare Nebius Group NV (NBIS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs Regeneron Pharmaceuticals Inc — how do they compare? Nebius Group NV trades at $223.64 (market cap $49.06B), while Regeneron Pharmaceuticals Inc trades at $794.9 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals.
| NBIS | REGN | |
|---|---|---|
Market Cap | $49.06B | $82.06B |
Sector | Technology | Health |
52-Week High | $286.69 | $812.27 |
52-Week Low | $64.06 | $555.51 |
Enterprise Value | $49.26B | $76.77B |
Dividend Yield | — | 0.47% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
